报价延迟最少15分钟:2026/08/14 14:21 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
25.975 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.68/-2.57
|
|
企业价值
843.47M
|
| 资产负债 |
|
每股账面净值
6.95
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company isdeveloping two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery. |
